

Publication date: 30th of June 2023

	Full Name <i>(Art. 1.01)</i>	HCPs: City of Principal Practice HCOs: city where registered <i>(Art. 3)</i>	Country of Principal Practice <i>(Schedule 1)</i>	Principal Practice Address <i>(Art. 3)</i>	Unique country local identifier <i>OPTIONAL</i> <i>(Art. 3)</i>	Donations and Grants to HCOs <i>(Art. 3.01.1.a)</i>	Fee for service and consultancy <i>(Art. 3.01.1.c & 3.01.2.c)</i>			TOTAL <i>OPTIONAL (EUR)</i>			
							Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accomodation		Fees	Related expenses agreed in the fee for service or consultancy contract	
HCPs	<i>INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)</i>												
	-	-	-	-	-	-	-	-	-	-	-	-	
	<i>OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons</i>												
	Aggregate amount attributable to transfers of value to such Recipients - <i>Art. 3.2</i>						N/A	N/A	-	-	15,704	-	
	Number of Recipients in aggregate disclosure- <i>Art. 3.2</i>						N/A	N/A	-	-	16	-	
% of the number Recipients included in the aggregate disclosure in the total number of Recipients disclosed- <i>Art. 3.2</i>						N/A	N/A	-	-	100	-		
HCOs	<i>INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)</i>												
	-	-	-	-	-	-	-	-	-	-	-	-	
	<i>OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons</i>												
	Aggregate amount attributable to transfers of value to such Recipients - <i>Art. 3.2</i>						2,796	13,333	-	-	-	-	
	Number of Recipients in aggregate disclosure- <i>Art. 3.2</i>						4	12	-	-	-	-	
% of the number Recipients included in the aggregate disclosure in the total number of Recipients disclosed- <i>Art. 3.2</i>						100	100	-	-	-	-		
R&D	AGGREGATE DISCLOSURE												
	Transfers of Value re Research & Development as defined - Article 3.04 and Schedule 1										-		